echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > HGF monoclonal antibody is accredited by FDA Fast Track

    HGF monoclonal antibody is accredited by FDA Fast Track

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    On September 20, AVEO Oncology announced that the FDA granted the company a fast track designation for the targeting HGF monoclonal antibody ficlatuzumab for the treatment of patients with recurrent or recurrent head and neck squamous cell carcinoma (R/R HNSCC)


    Ficlatuzumab (AV-299) is a potent hepatocyte growth factor (HGF) immunoglobulin G1 (IgG1) inhibitory antibody under investigation, which can bind to HGF ligands with high affinity and specificity


    In June 2021, the company announced the use of ficlatuzumab as a single agent or combined with EGFR monoclonal antibody cetuximab for relapsed or refractory metastatic head and neck squamous cells that had previously received immunotherapy, chemotherapy, and cetuximab.


    Positive results were obtained in the Ficlatuzumab combined with cetuximab group.


    Ficlatuzumab combined with cetuximab is well tolerated and has similar expected toxicity to HGF/cMet inhibitors.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.